MBX Biosciences (MBX) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MBX Biosciences (MBX) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 83.0% versus a loss of 29.2%. MBX Biosciences is the larger company by market cap ($2.46 billion vs $2.25 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBX | RCUS |
|---|---|---|
| Share price | $49.55 | $15.62 |
| Market cap | $2.46B | $2.25B |
| 1-day change | -7.23% | -1.01% |
| YTD return | +57.10% | -34.45% |
| 1-year return | +82.98% | -29.16% |
| 5-year return | — | -66.31% |
| EPS (TTM) | $-3.03 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $247.00M |
| Revenue growth (YoY) | — | -4.26% |
| Net income (latest FY) | $-87.00M | $-353.00M |
| Operating margin | — | -156.28% |
| Net margin | — | -142.91% |
| 52-week high | $72.64 | $31.74 |
| 52-week low | $26.14 | $15.56 |
| Distance from 52-week high | -31.79% | -50.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +91.91% | +162.48% |
| Average volume | 532.80K | 1.85M |
| Shares outstanding | 49.66M | 143.99M |
| Employees | 63 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed RCUS by 112.1 percentage points over the past year.
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
MBX vs RCUS FAQ
Which is bigger, MBX Biosciences or Arcus Biosciences?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.46B compared with $2.25B for Arcus Biosciences (RCUS).
Which stock has performed better over the past year, MBX or RCUS?
MBX returned +82.98% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.
Are MBX Biosciences and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.